IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $24.35 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato la concessione di opzioni azionarie di incentivo a un nuovo dipendente. Il Comitato per la Retribuzione ha approvato opzioni azionarie non qualificate per l'acquisto di 31.400 azioni ordinarie nell'ambito del Piano di Incentivi per l'Assunzione 2023 dell'azienda.
Le opzioni sono state concesse a un prezzo di esercizio di 24,35 $ per azione, corrispondente al prezzo di chiusura di IDEAYA nella data di assegnazione. Le opzioni hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei tre anni successivi, subordinatamente alla continuazione del rapporto di lavoro.
IDEAYA Biosciences (NASDAQ: IDYA) anunció la concesión de opciones sobre acciones como incentivo a un nuevo empleado. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 31,400 acciones ordinarias bajo el Plan de Incentivos por Contratación 2023 de la empresa.
Las opciones se otorgaron a un precio de ejercicio de $24.35 por acción, igualando el precio de cierre de IDEAYA en la fecha de concesión. Las opciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con un 25% consolidado después del primer año y el 75% restante consolidándose mensualmente durante los siguientes tres años, sujeto a la continuidad del empleo.
IDEAYA 바이오사이언시스 (NASDAQ: IDYA)는 신규 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 회사의 2023년 고용 유인 인센티브 상 계획에 따라 31,400주의 보통주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
주식 옵션은 부여일 IDEAYA의 종가와 일치하는 주당 24.35달러의 행사가격으로 부여되었습니다. 옵션은 10년 만기이며 4년에 걸쳐 권리가 부여되며, 첫 해에 25%가 부여되고 나머지 75%는 이후 3년 동안 매월 부여되며, 계속 고용되는 조건입니다.
IDEAYA Biosciences (NASDAQ : IDYA) a annoncé l’attribution d’options d’achat d’actions à titre d’incitation à un nouvel employé. Le comité de rémunération a approuvé des options d’achat d’actions non qualifiées permettant d’acquérir 31 400 actions ordinaires dans le cadre du Plan d’incitation à l’embauche 2023 de la société.
Les options ont été accordées à un prix d’exercice de 24,35 $ par action, correspondant au cours de clôture d’IDEAYA à la date d’attribution. Les options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquis après la première année et les 75 % restants acquis mensuellement au cours des trois années suivantes, sous réserve de la poursuite de l’emploi.
IDEAYA Biosciences (NASDAQ: IDYA) gab die Gewährung von Anreizaktienoptionen an einen neuen Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 31.400 Aktien des Stammkapitals im Rahmen des Beschäftigungsanreizplans 2023 des Unternehmens.
Die Aktienoptionen wurden zu einem Ausübungspreis von 24,35 $ pro Aktie gewährt, entsprechend dem Schlusskurs von IDEAYA am Gewährungstag. Die Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre erworben, wobei 25 % nach dem ersten Jahr und die restlichen 75 % monatlich über die folgenden drei Jahre erworben werden, vorbehaltlich einer fortgesetzten Beschäftigung.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302519217.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What stock options did IDEAYA Biosciences (IDYA) grant to its new employee?
What is the vesting schedule for IDEAYA's (IDYA) newly granted stock options?
What is the purpose of IDEAYA's (IDYA) 2023 Inducement Plan?
How long is the term of IDEAYA's (IDYA) newly granted stock options?
